Home » Stocks » TARS

Tarsus Pharmaceuticals, Inc. (TARS)

Stock Price: $28.54 USD 0.03 (0.11%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 603.42M
Revenue (ttm) n/a
Net Income (ttm) -26.81M
Shares Out 20.70M
EPS (ttm) -4.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $28.54
Previous Close $28.51
Change ($) 0.03
Change (%) 0.11%
Day's Open 28.37
Day's Range 28.12 - 29.78
Day's Volume 17,327
52-Week Range 15.32 - 63.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention

2 days ago - GlobeNewsWire

Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans

3 days ago - GlobeNewsWire

IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven ...

1 week ago - GlobeNewsWire

Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021

1 month ago - GlobeNewsWire

Tarsus Pharmaceuticals Inc (NASDAQ: TARS) and LianBio have announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 (lo...

1 month ago - Benzinga

Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis and 70 million patients with Meibomian Gland Disease in China, the world's second largest healthcare market De...

1 month ago - GlobeNewsWire

IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

3 months ago - GlobeNewsWire

IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

3 months ago - GlobeNewsWire

IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

4 months ago - GlobeNewsWire

The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021 The Company began enrolling patients in Saturn-1 in Se...

4 months ago - GlobeNewsWire

IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

4 months ago - GlobeNewsWire

IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

5 months ago - GlobeNewsWire

IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthro...

5 months ago - GlobeNewsWire

IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic...

6 months ago - GlobeNewsWire

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, CDAK, EBC, OPT, PRAX, SPEL
6 months ago - Seeking Alpha

IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic...

6 months ago - GlobeNewsWire

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
TARS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is 42.20, which is an increase of 47.86% from the latest price.

Price Target
$42.20
(47.86% upside)
Analyst Consensus: Strong Buy